Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-953.6%-551pp-1,002.9%-616pp-575.8%-27.7pp-270%+2,541pp-402.5%+2,492pp
Net margin-942.8%-545pp-905.7%-375pp-627.3%-35.2pp-258.9%+2,831pp-397.5%+2,935pp
Returns
Return on equity-29.5%+2.0pp-28.3%+17.9pp-39.9%+16.0pp-28.4%-31.5%
Efficiency
Asset turnover0.1×
Liquidity
Current ratio9.8×-10.2×7.9×-0.2×12.6×+2.0×21.1×20×
Leverage
Debt-to-equity0.0×0.0×0.0×
Valuation
Market capitalization$3.68B+63.7%$3.98B+44.6%$3.2B+114%$2.07B+19.5%$2.25B+5.6%
Price / sales163.1×+115×176.8×+116×90.9×+46.4×32.3×-201×47.7×-262×
Price / book5.5×+2.6×5.8×+2.2×4.4×+0.5×2.7×-1.8×2.9×-2.3×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do NewAmsterdam Pharma Company's ratios come from?
Every ratio is computed from NewAmsterdam Pharma Company's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.